Abstract | BACKGROUND:
Chromoblastomycosis is a chronic subcutaneous mycosis that occurs more frequently in tropical and subtropical areas and is caused by a group of dematiaceous fungi. It is a difficult-to-treat mycosis with low cure rates and a high rate of relapses. OBJECTIVE: METHODS AND RESULTS: We included four cases of chromoblastomycosis, proved clinically and mycologically, that are presented herein; three of them caused by Fonsecaea pedrosoi and one by Phialophora verrucosa. Two had a small extension and the other two were of medium and large extension. Oral terbinafine was administered at a dose of 500 mg/day, which was reduced to half in two of the cases once an 80% improvement had been reached; in the third case the initial dose was maintained, and in the fourth case the dose was increased to 750 mg/day. Three cases reached clinical and mycological cure in a mean treatment period of 7 months, the fourth case reached a significant improvement only after 1.2 years of treatment. The medication was well tolerated; no liver alterations occurred; only one patient suffered mild dyspepsia. CONCLUSION:
|
Authors | A Bonifaz, A Saúl, V Paredes-Solis, J Araiza, L Fierro-Arias |
Journal | The Journal of dermatological treatment
(J Dermatolog Treat)
Vol. 16
Issue 1
Pg. 47-51
(Feb 2005)
ISSN: 0954-6634 [Print] England |
PMID | 15897168
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antifungal Agents
- Naphthalenes
- Terbinafine
|
Topics |
- Administration, Oral
- Adult
- Aged
- Agricultural Workers' Diseases
(drug therapy)
- Antifungal Agents
(administration & dosage, therapeutic use)
- Chromoblastomycosis
(drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Naphthalenes
(administration & dosage, therapeutic use)
- Phialophora
(isolation & purification)
- Terbinafine
- Treatment Outcome
|